The present invention relates to a complement inhibitor for use in a method of preventing or ameliorating an ocular disease associated with complement activation in a subject, wherein the complement inhibitor is an antibody that specifically binds to complement component C5a, an antigen-binding fragment thereof, a nucleic acid encoding said antibody or said fragment, or a siRNA specific for C5a. Further provided herein is use of the complement inhibitor for the preparation of a pharmaceutical composition for preventing or ameliorating an ocular disease associated with compliment activation in a subject.
